People affected by leukemia and health care professionals who advocate for personalized medicine options could benefit from technology that is being developed with funding from a National Institutes of Health grant.
Tymora Analytical Operations LLC, Purdue University and St. Jude Children’s Research Hospital have been awarded a one-year, $300,000 Phase I STTR grant from the NIH. The groups will develop technology that could pinpoint the proteins inside cells affected by the disease so treatments can be more targeted.
“By showing which proteins are affected by the disease, this platform can highlight the differences between leukemia cells,” said Anton Iliuk, chief technology officer of Tymora Analytical Operations. “Identifying these differences would enable doctors to prescribe individualized, more precise drug treatment regimens for each patient.”
The new platform will be developed from the company’s pIMAGO and PolyMAC technologies.
The principal investigator for the project is W. Andy Tao, associate professor of biochemistry in Purdue’s College of Agriculture. He also is chief scientific officer at Tymora Analytical Operations. The co-investigator is Jun J. Yang of St. Jude Children’s Research Hospital in Memphis.
Article adapted by Medical News Today from original press release. Source: Purdue University
Visit our lymphoma / leukemia / myeloma section for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:MLA
University, Purdue. “NIH grant could develop technology to help personalize leukemia treatments.” Medical News Today. MediLexicon, Intl., 4 Oct. 2013. Web.7 Oct. 2013. <http://www.medicalnewstoday.com/releases/266971.php>
University, P. (2013, October 4). “NIH grant could develop technology to help personalize leukemia treatments.” Medical News Today. Retrieved fromhttp://www.medicalnewstoday.com/releases/266971.php.
Please note: If no author information is provided, the source is cited instead.
(Hover over the stars then click to rate)
Patient / Public:or
Add Your Opinion On This Article‘NIH grant could develop technology to help personalize leukemia treatments’Please note that we publish your name, but we do not publish your email address. It is only used to let
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.
Lymphoma / Leukemia / Myeloma
What Is Lymphoma?
Lymphoma is a type of cancer that begins in immune system cells called lymphocytes. Like other cancers, lymphoma occurs when lymphocytes are in a state of uncontrolled cell growth and multiplication.
Most Popular Articles
Follow Our Lymphoma News On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Lymphoma / Leukemia / Myeloma Twitter account
and select the ‘follow’ option.
View list of all ‘What Is…’ articles »